- Home
- TIMB vs EXEL Comparison
TIMB vs EXEL Comparison
Compare TIMB & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIMB
- EXEL
- Stock Information
- Founded
- TIMB 1998
- EXEL 1994
- Country
- TIMB Brazil
- EXEL United States
- Employees
- TIMB N/A
- EXEL N/A
- Industry
- TIMB Telecommunications Equipment
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TIMB Telecommunications
- EXEL Health Care
- Exchange
- TIMB Nasdaq
- EXEL Nasdaq
- Market Cap
- TIMB 11.1B
- EXEL 11.1B
- IPO Year
- TIMB 1998
- EXEL 2000
- Fundamental
- Price
- TIMB $22.81
- EXEL $42.67
- Analyst Decision
- TIMB Hold
- EXEL Buy
- Analyst Count
- TIMB 5
- EXEL 24
- Target Price
- TIMB $22.75
- EXEL $44.73
- AVG Volume (30 Days)
- TIMB 370.0K
- EXEL 2.7M
- Earning Date
- TIMB 11-03-2025
- EXEL 11-04-2025
- Dividend Yield
- TIMB 6.20%
- EXEL N/A
- EPS Growth
- TIMB 26.01
- EXEL 53.55
- EPS
- TIMB 0.31
- EXEL 2.38
- Revenue
- TIMB $4,941,546,695.00
- EXEL $2,288,218,000.00
- Revenue This Year
- TIMB $8.05
- EXEL $9.14
- Revenue Next Year
- TIMB $5.26
- EXEL $12.51
- P/E Ratio
- TIMB $14.53
- EXEL $17.89
- Revenue Growth
- TIMB 4.96
- EXEL 9.93
- 52 Week Low
- TIMB $11.32
- EXEL $31.90
- 52 Week High
- TIMB $23.88
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- TIMB 51.36
- EXEL 59.85
- Support Level
- TIMB $22.28
- EXEL $41.65
- Resistance Level
- TIMB $23.53
- EXEL $42.99
- Average True Range (ATR)
- TIMB 0.42
- EXEL 1.42
- MACD
- TIMB -0.11
- EXEL 0.12
- Stochastic Oscillator
- TIMB 33.86
- EXEL 83.38
About TIMB TIM S.A. (Each representing 5)
TIM, which is 67%-owned by Telecom Italia, is the third largest wireless carrier in Brazil, with 62 million subscribers, equal to about 24% of the market. The firm also owns 49% of I-Systems, an infrastructure partnership that is expanding its network footprint across Brazil. I-Systems can provide broadband service to about 9 million locations, equal to 10%-15% of the country. TIM leases capacity on the venture's network to serve retail broadband customers under the UltraFibra brand. TIM also resells fiber network access from other providers, including Oi's former infrastructure business V.tal.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.